PYNNACLE phase II clinical trial protocol: rezatapopt (PC14586) monotherapy in advanced or metastatic solid tumors with a TP53 Y220C mutation

Key Points

• Rezapatopting shows promise in targeting tumors with the TP53 Y220C mutation, enhancing treatment options.
• Participants with advanced solid tumors will be evaluated for safety and efficacy of PC14586 treatment.
• Phase II clinical trial protocol outlines methods for measuring treatment outcomes in this specific patient group.
• Findings may enable targeted therapies for advanced metastatic tumors, addressing a pressing need in oncology.